
Thermo Fisher (TMO) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
10.4B
Gross Profit
4.2B
40.86%
Operating Income
1.8B
17.51%
Net Income
1.5B
14.58%
EPS (Diluted)
$3.98
Balance Sheet Metrics
Total Assets
99.0B
Total Liabilities
49.6B
Shareholders Equity
49.5B
Debt to Equity
1.00
Cash Flow Metrics
Operating Cash Flow
2.1B
Free Cash Flow
361.0M
Revenue & Profitability Trend
Thermo Fisher Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 42.9B | 42.9B | 44.9B | 39.2B | 32.2B |
Cost of Goods Sold | 25.2B | 25.8B | 25.9B | 19.6B | 16.2B |
Gross Profit | 17.7B | 17.1B | 19.0B | 19.6B | 16.0B |
Gross Margin % | 41.3% | 39.9% | 42.2% | 50.1% | 49.7% |
Operating Expenses | |||||
Research & Development | 1.4B | 1.3B | 1.5B | 1.4B | 1.2B |
Selling, General & Administrative | 8.6B | 8.4B | 9.0B | 8.0B | 6.9B |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 10.0B | 9.8B | 10.5B | 9.4B | 8.1B |
Operating Income | 7.7B | 7.3B | 8.5B | 10.2B | 7.9B |
Operating Margin % | 18.0% | 17.1% | 18.9% | 26.1% | 24.5% |
Non-Operating Items | |||||
Interest Income | 1.1B | 879.0M | 272.0M | 43.0M | 65.0M |
Interest Expense | 1.4B | 1.4B | 726.0M | 536.0M | 553.0M |
Other Non-Operating Income | -367.0M | -524.0M | -218.0M | -891.0M | -175.0M |
Pre-tax Income | 7.0B | 6.3B | 7.8B | 8.8B | 7.2B |
Income Tax | 657.0M | 284.0M | 703.0M | 1.1B | 850.0M |
Effective Tax Rate % | 9.3% | 4.5% | 9.0% | 12.5% | 11.8% |
Net Income | 6.3B | 6.0B | 7.0B | 7.7B | 6.4B |
Net Margin % | 14.8% | 13.9% | 15.5% | 19.7% | 19.8% |
Key Metrics | |||||
EBITDA | 11.9B | 11.5B | 12.1B | 12.2B | 10.2B |
EPS (Basic) | $16.58 | $15.52 | $17.75 | $19.62 | $16.09 |
EPS (Diluted) | $16.53 | $15.45 | $17.63 | $19.46 | $15.96 |
Basic Shares Outstanding | 382000000 | 386000000 | 392000000 | 394000000 | 396000000 |
Diluted Shares Outstanding | 382000000 | 386000000 | 392000000 | 394000000 | 396000000 |
Income Statement Trend
Thermo Fisher Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 4.0B | 8.1B | 8.5B | 4.5B | 10.3B |
Short-term Investments | 1.6B | - | - | - | - |
Accounts Receivable | 8.2B | 8.2B | 8.1B | 8.0B | 5.7B |
Inventory | 5.0B | 5.1B | 5.6B | 5.1B | 4.0B |
Other Current Assets | 2.0B | 1.8B | 1.6B | 1.6B | 1.1B |
Total Current Assets | 22.1B | 24.6B | 25.2B | 20.1B | 22.0B |
Non-Current Assets | |||||
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 |
Goodwill | 107.2B | 104.7B | 99.8B | 104.0B | 64.8B |
Intangible Assets | 15.5B | 16.7B | 17.4B | 20.1B | 12.7B |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 4.5B | 4.0B | 4.0B | 4.6B | 2.5B |
Total Non-Current Assets | 75.2B | 74.1B | 71.9B | 75.0B | 47.1B |
Total Assets | 97.3B | 98.7B | 97.2B | 95.1B | 69.1B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 3.1B | 2.9B | 3.4B | 2.9B | 2.2B |
Short-term Debt | 2.2B | 3.6B | 5.6B | 2.5B | 2.6B |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | - |
Total Current Liabilities | 13.3B | 14.0B | 17.0B | 13.4B | 10.3B |
Non-Current Liabilities | |||||
Long-term Debt | 29.1B | 31.3B | 28.9B | 32.3B | 19.1B |
Deferred Tax Liabilities | 1.3B | 1.9B | 2.8B | 3.8B | 1.8B |
Other Non-Current Liabilities | 4.0B | 4.6B | 4.2B | 4.5B | 3.3B |
Total Non-Current Liabilities | 34.3B | 37.9B | 36.0B | 40.7B | 24.2B |
Total Liabilities | 47.6B | 51.9B | 53.0B | 54.1B | 34.5B |
Equity | |||||
Common Stock | 444.0M | 442.0M | 441.0M | 439.0M | 437.0M |
Retained Earnings | 53.1B | 47.4B | 41.9B | 35.4B | 28.1B |
Treasury Stock | 19.2B | 15.1B | 12.0B | 8.9B | 6.8B |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 49.7B | 46.8B | 44.1B | 41.0B | 34.5B |
Key Metrics | |||||
Total Debt | 31.3B | 34.9B | 34.5B | 34.9B | 21.7B |
Working Capital | 8.8B | 10.6B | 8.2B | 6.7B | 11.7B |
Balance Sheet Composition
Thermo Fisher Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 6.3B | 6.0B | 7.0B | 7.7B | 6.4B |
Depreciation & Amortization | 3.1B | 3.4B | 3.4B | 2.6B | 2.3B |
Stock-Based Compensation | 301.0M | 278.0M | 307.0M | 230.0M | 196.0M |
Working Capital Changes | -334.0M | -495.0M | -1.0B | -1.5B | -299.0M |
Operating Cash Flow | 8.7B | 8.4B | 9.1B | 8.5B | 8.3B |
Investing Activities | |||||
Capital Expenditures | -1.3B | -1.4B | -2.2B | -2.5B | -1.5B |
Acquisitions | -3.1B | -3.7B | -39.0M | -19.4B | -38.0M |
Investment Purchases | -3.4B | - | - | - | - |
Investment Sales | 2.0B | 70.0M | 15.0M | 8.0M | - |
Investing Cash Flow | -5.8B | -5.1B | -2.2B | -21.9B | -1.5B |
Financing Activities | |||||
Share Repurchases | -4.0B | -3.0B | -3.0B | -2.0B | -1.5B |
Dividends Paid | -583.0M | -523.0M | -455.0M | -395.0M | -337.0M |
Debt Issuance | 1.2B | 5.9B | 3.2B | 18.1B | 3.5B |
Debt Repayment | -3.6B | -7.7B | -4.1B | -11.7B | -1.1B |
Financing Cash Flow | -6.8B | -5.6B | -6.5B | 6.6B | 376.0M |
Free Cash Flow | 7.3B | 6.9B | 6.9B | 6.8B | 6.8B |
Net Change in Cash | -4.0B | -2.3B | 469.0M | -6.8B | 7.2B |
Cash Flow Trend
Thermo Fisher Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
28.25
Forward P/E
20.82
Price to Book
3.66
Price to Sales
4.27
PEG Ratio
4.97
Profitability Ratios
Profit Margin
15.24%
Operating Margin
17.84%
Return on Equity
13.42%
Return on Assets
4.97%
Financial Health
Current Ratio
1.93
Debt to Equity
69.62
Beta
0.75
Per Share Data
EPS (TTM)
$17.31
Book Value per Share
$133.77
Revenue per Share
$113.72
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
tmo | 184.7B | 28.25 | 3.66 | 13.42% | 15.24% | 69.62 |
Danaher | 151.0B | 44.88 | 2.89 | 6.68% | 14.21% | 35.45 |
Idexx Laboratories | 52.1B | 54.06 | 35.76 | 64.87% | 24.41% | 84.81 |
Agilent Technologies | 33.9B | 29.36 | 5.52 | 18.88% | 17.59% | 60.04 |
Iqvia Holdings | 32.5B | 27.69 | 5.62 | 19.79% | 7.88% | 272.12 |
Mettler-Toledo | 27.0B | 33.22 | - | -680.23% | 21.46% | -8.44 |
Financial data is updated regularly. All figures are in the company's reporting currency.